DMIIR
Drugs Made In America Acquisition II Corp. RightNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
—
52W High
$0.17
52W Low
$0.06
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Drugs Made In America Acquisition II Corp. Right
Drugs Made In America Acquisition II Corp. Right (DMIIR) is a special purpose acquisition company (SPAC) dedicated to identifying and merging with innovative firms in the pharmaceutical industry, with a focus on boosting domestic drug manufacturing capabilities. Led by a highly experienced management team, DMIIR is strategically positioned to address the growing demand for accessible and affordable medications produced within the United States. Through targeted acquisitions, DMIIR aims to create substantial shareholder value while fostering the development of critical healthcare infrastructure to enhance the resilience of the American healthcare system.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | -812,113 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -0.32% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.28 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $50.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
178.22%
HV 20-Day
125.53%
HV 30-Day
107.35%
HV 60-Day
129.00%
HV Rank
—
Volatility is currently expanding
Data last updated: 5/25/2026